Navigation Links
Dendreon Announces Pricing of Common Stock Offering
Date:12/10/2009

and Exchange Commission (the "SEC"). Copies of the prospectus supplement and related base prospectus for this offering, when available, may be obtained by contacting: J.P. Morgan Securities Inc., c/o Broadridge Financial Solutions, 1155 Long Island Avenue, Edgewood, New York 11717, or by calling 1-866-803-9204; or Deutsche Bank Securities Inc., Prospectus Department, Harborside Financial Center, 100 Plaza One, Jersey City, New Jersey 07311-3988, or by calling 1-800-503-4611. An electronic copy of the prospectus supplement and related base prospectus for the offering will also be available on the SEC's website, www.sec.gov.

This press release shall not constitute an offer to sell or the solicitation of an offer to buy nor shall there be any sale of the securities in any jurisdiction in which such offer, solicitation or sale would be unlawful. The offering of these securities will be made only by means of a prospectus supplement and accompanying base prospectus. The securities being offered have not been approved or disapproved by any regulatory authority, nor has any such authority passed upon the accuracy or adequacy of the registration statement or the prospectus contained therein.

About Dendreon

Dendreon Corporation is a biotechnology company whose mission is to target cancer and transform lives through the discovery, development and commercialization of novel therapeutics. Dendreon applies its expertise in antigen identification, engineering and cell processing to produce ACI product candidates designed to stimulate an immune response. Dendreon is also developing an orally-available small molecule that targets TRPM8 that could be applicable to multiple types of cancer as well as benign prostatic hyperplasia. Dendreon has its headquarters in Seattle, Washington, and is traded on the Nasdaq Global Market under the symbol DNDN.

This news release contains forward-looking statements that are subject to risks
'/>"/>

SOURCE Dendreon Corporation
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Dendreon Appoints Hans Bishop as Chief Operating Officer
2. Dendreon Announces Proposed Public Offering of Common Stock
3. Dendreon Receives FDA Acknowledgement of Complete Response
4. Dendreon Reports Third Quarter 2009 Financial Results and Continuing Progress Toward PROVENGE Commercialization
5. Dendreon Completes Submission of Biologics License Application for PROVENGE
6. Dendreon Announces Webcast Presentations at Upcoming Investor Conferences
7. Dendreon Announces Webcast Presentations at Upcoming Investor Conferences
8. Dendreon Announces Analyst Day Webcast Presentation to be Held on September 24, 2009
9. Dendreon Reports Second Quarter 2009 Financial Results
10. Dendreon Signs Lease for New Manufacturing Facility in Atlanta
11. Dendreon to Hold Conference Call on Tuesday, August 11, 2009 at 11:30 AM ET
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/17/2014)... 17, 2014 Gene synthesis and ... has entered into a technology access and services ... apply DNA2.0’s proprietary protein engineering technology, known as ... “We are extremely excited that the global leader ... This proprietary bioengineering technology has now been validated ...
(Date:12/17/2014)... -- CASI Pharmaceuticals, Inc. (Nasdaq: CASI ), ... commercialization of innovative therapeutics addressing cancer and other unmet ... commercial focus on China , today ... meeting with the U.S. Food and Drug Administration (FDA) ... 2015.  During this meeting the Company will seek guidance ...
(Date:12/15/2014)... Israel , Dec. 15, 2014  BrainStorm ... leading developer of adult stem cell technologies for neurodegenerative ... Ltd. was awarded a grant of approximately $1.1 million ... Chief Scientist (OCS).  This is the eighth year that ... the Office of the Chief Scientist, which is part ...
(Date:12/15/2014)... , Dec. 15, 2014  Ascendis Pharma ... TransCon technology to address significant unmet medical needs, ... ongoing Phase 2 pediatric study to evaluate once-weekly ... deficiency, or GHD.  This interim analysis consists of ... total enrollment in the study, completing all six ...
Breaking Biology Technology:ADM and DNA2.0 Enter Into Protein Engineering Technology Access and Service Agreement 2CASI Pharmaceuticals Granted Type C Meeting With U.S. FDA For ENMD-2076 In Fibrolamellar Carcinoma 2CASI Pharmaceuticals Granted Type C Meeting With U.S. FDA For ENMD-2076 In Fibrolamellar Carcinoma 3CASI Pharmaceuticals Granted Type C Meeting With U.S. FDA For ENMD-2076 In Fibrolamellar Carcinoma 4CASI Pharmaceuticals Granted Type C Meeting With U.S. FDA For ENMD-2076 In Fibrolamellar Carcinoma 5BrainStorm Receives $1,100,000 for its 8th Annual Non-Dilutive Grant from Israel's Chief Scientist Office 2BrainStorm Receives $1,100,000 for its 8th Annual Non-Dilutive Grant from Israel's Chief Scientist Office 3Ascendis Pharma A/S Announces Positive Six-Month Interim Results from a Phase 2 Pediatric Study of Once-Weekly TransCon Growth Hormone for the Treatment of Growth Hormone Deficiency 2Ascendis Pharma A/S Announces Positive Six-Month Interim Results from a Phase 2 Pediatric Study of Once-Weekly TransCon Growth Hormone for the Treatment of Growth Hormone Deficiency 3Ascendis Pharma A/S Announces Positive Six-Month Interim Results from a Phase 2 Pediatric Study of Once-Weekly TransCon Growth Hormone for the Treatment of Growth Hormone Deficiency 4
... - Injured soldiers in Iraq and Afghanistan are becoming ... a Madison-based company is developing counter-measures. , ,With a ... U.S. Army in hand, ConjuGon, Inc. ... antibiotic-resistant bacterial infections. , ,"We are pleased that the ...
... White Sox this year and as for the Cubs ... What we cannot "wait until next year" for is some real ... Chicago. , ,There should be as much buzz, if not more, ... teams that didn't even make the playoffs, but maybe the media ...
... - Patent law is esoteric territory, but a Madison court ... in the process it might be giving smaller drug companies ... , ,The most recent example occurred last month. After a ... jury in U.S. District Court for the Western District ...
Cached Biology Technology:Wait `till next year OK for baseball, not broadband 2Wait `till next year OK for baseball, not broadband 3Wait `till next year OK for baseball, not broadband 4Wait `till next year OK for baseball, not broadband 5With patents, Wisconsin court gaining reputation as a "rocket docket" 2With patents, Wisconsin court gaining reputation as a "rocket docket" 3With patents, Wisconsin court gaining reputation as a "rocket docket" 4
(Date:12/10/2014)...  Wake Forest Baptist Medical Center today announced plans for ... Medicine. Funding for this $50 million capital project is ... publicly launched next summer. The medical ... series R.J. Reynolds Tobacco Company complex, adjacent to 525@vine ... with plans to be ready to welcome medical students ...
(Date:12/5/2014)... Calif. , Dec. 4, 2014 ... has boosted investments in new testing and inspection ... also given rise to a range of innovative ... the requirements of Generation Y, which is generally ... As a result, product development strategies of test ...
(Date:12/3/2014)... Ariz. , Dec. 2, 2014 As ... hand readers, Inception Technologies is pleased to announce the ... easier for customers to collect the workforce data that ... problems that have been left by existing readers. Many ... user interface, connectivity and modern technology. Older models force ...
Breaking Biology News(10 mins):Wake Forest Baptist to Build New Medical Education Facility In Wake Forest Innovation Quarter 2Wake Forest Baptist to Build New Medical Education Facility In Wake Forest Innovation Quarter 3Wake Forest Baptist to Build New Medical Education Facility In Wake Forest Innovation Quarter 4Emerging Technologies Enable Smarter Monitoring of Assets, Push Industrial Testing, Inspection and Monitoring Market 2Emerging Technologies Enable Smarter Monitoring of Assets, Push Industrial Testing, Inspection and Monitoring Market 3Emerging Technologies Enable Smarter Monitoring of Assets, Push Industrial Testing, Inspection and Monitoring Market 4Inception Technologies to Release New Biometric Reader 2
... cellsas indicated by a molecular imaging techniquecould tell researchers ... headaches and psychosis in schizophrenic patients, occur and provide ... two studies published in the November issue of the ... positron emission tomography (PET)a noninvasive molecular imaging techniqueresearchers were ...
... When 100 m sprinters launches themselves from the starting blocks, ... few strides. Acceleration through the first few strides is the ... by an American football star, who sprints in his position ... his technique and training regime, Piazza decided to focus on ...
... have confirmed that the largest bat in Europe, ... the Late Pleistocene (between 120,000 and 10,000 years ago). ... at Abrc Roman (Barcelona) prove that this bat had ... than it does today, having declined due to the ...
Cached Biology News:Unlocking mysteries of the brain with PET 2Short heels make elite sprinters super speedy 2The largest bat in Europe inhabited northeastern Spain more than 10,000 years ago 2
Collected from sexually mature, mixed sex, mixed breed guinea pigs. Pricing: $120/unit for 1 - 10 units...
Active GST Protein...
Marmoset plasma and serum - various quantities available...
Porcine Serum Available Anticoagulants: N-02: Citrate N-04: Heparin (Na) N-06: K2EDTA N-08: Potassium Oxalate N-10: EDTA (Na) N-03: Alsevers N-05: ACD N-07: CPD N-09: K3EDTA N-11...
Biology Products: